Q04206 (TF65_HUMAN) Homo sapiens (Human)

Transcription factor p65 UniProtKBInterProSTRINGInteractive Modelling

551 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4); 1 identical sequence: Gorilla gorilla gorilla: G3SHV6

Available Structures

88 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
I-KAPPA-B-ALPHA/NF-KAPPA-B COMPLEX Heteromer
P19838; P25963;
20-314
99.66
Crystal Structure of NFkB, IRF7, IRF3 bound to the interferon-b enhancer Heteromer
P19838; Q14653; Q92985;
20-291
100
Crystal structure of a higher-order complex of p50:RelA bound to the HIV-1 LTR Heteromer
P19838;
20-291
97.43
NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and the transacti… Heteromer
P32776;
521-551
96.77
NMR structure of the complex between the KIX domain of CBP and the transactivation domain 1 of p65 Heteromer
P45481;
521-551
96.77
Structure of importin a3 bound to the p50- and p65-NLSs Heteromer
O00629; P19838;
299-311
100
solution structures of BRD4 second bromodomain with NF-kB-K310ac peptide Heteromer
O60885;
304-316
100
14-3-3 sigma with RelA/p65 binding site pS45 in complex with DP005 Heteromer
P31947;
42-50
88.89CL;0V4;
14-3-3 sigma with RelA/p65 binding site pS45 Heteromer
P31947;
43-51
88.89GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-192 Heteromer
P31947;
43-51
88.89V2N;V2K;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-046 Heteromer
P31947;
43-51
88.89CL;V0T;CA;GOL;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-180 Heteromer
P31947;
43-51
88.89TVB;CA;CL;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-187 Heteromer
P31947;
43-51
88.89TW8;CA;CL;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-185 Heteromer
P31947;
43-51
88.89UT8;CL;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-184 Heteromer
P31947;
43-51
88.89UVK;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-182 Heteromer
P31947;
43-51
88.89UVZ;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-188 Heteromer
P31947;
43-51
88.89UST;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-183 Heteromer
P31947;
43-51
88.89UVE;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-179 Heteromer
P31947;
43-51
88.89TQW;GOL;CA;CL;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-181 Heteromer
P31947;
43-51
88.89UVQ;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-186 Heteromer
P31947;
43-51
88.89USW;CL;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521 Heteromer
P31947;
43-51
88.89L3Y;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound LvD1009 Heteromer
P31947;
43-51
88.89TJ8;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-069 Heteromer
P31947;
43-51
88.89CL;TZH;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-111 Heteromer
P31947;
43-51
88.89UON;UOT;PEG;CL;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-134 Heteromer
P31947;
43-51
88.89UVH;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-135 Heteromer
P31947;
43-51
88.89UHQ;GOL;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-154 Heteromer
P31947;
43-51
88.89TZW;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-131 Heteromer
P31947;
43-51
88.89UVB;MG;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-125 Heteromer
P31947;
43-51
88.89UWH;CA;CL;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-124 Heteromer
P31947;
43-51
88.89UGN;CA;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-142 Heteromer
P31947;
43-51
88.89TWQ;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-117 Heteromer
P31947;
43-51
88.89V0W;CL;MG;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-116 Heteromer
P31947;
43-51
88.89CL;CA;GOL;PEG;V1K;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-130 Heteromer
P31947;
43-51
88.89UVN;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-120 Heteromer
P31947;
43-51
88.89UXN;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-083 Heteromer
P31947;
43-51
88.89V48;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-097 Heteromer
P31947;
43-51
88.89V42;CA;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-133 Heteromer
P31947;
43-51
88.89UGE;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-080 Heteromer
P31947;
43-51
88.89V4N;CL;CA;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-096 Heteromer
P31947;
43-51
88.89V3Z;CL;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-127 Heteromer
P31947;
43-51
88.89UVT;CL;MG;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-126 Heteromer
P31947;
43-51
88.89UHN;CA;CL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-070 Heteromer
P31947;
43-51
88.89GOL;CA;UHZ;CL;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-153 Heteromer
P31947;
43-51
88.89U1B;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-157 Heteromer
P31947;
43-51
88.89V2E;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-132 Heteromer
P31947;
43-51
88.89GOL;CL;UG8;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-123 Heteromer
P31947;
43-51
88.89P7E;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-121 Heteromer
P31947;
43-51
88.89UWK;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-122 Heteromer
P31947;
43-51
88.89UWQ;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-044 Heteromer
P31947;
43-51
88.89CL;TZK;GOL;CA;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-028 Heteromer
P31947;
43-51
88.89CL;P5Q;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-033 Heteromer
P31947;
43-51
88.89CL;P6Z;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-037 Heteromer
P31947;
43-51
88.89CL;P6H;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-011 Heteromer
P31947;
43-51
88.89CL;P5N;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-175 Heteromer
P31947;
43-51
88.89CL;TWE;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-025 Heteromer
P31947;
43-51
88.89CL;L3S;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-158 Heteromer
P31947;
43-51
88.89CL;V2Q;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-161 Heteromer
P31947;
43-51
88.89CL;V32;MG;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-042 Heteromer
P31947;
43-51
88.89CL;V1E;CA;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-166 Heteromer
P31947;
43-51
88.89CL;V3N;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-176 Heteromer
P31947;
43-51
88.89CL;V4H;CA;PEG;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-164 Heteromer
P31947;
43-51
88.89CL;V3B;PEG;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-173 Heteromer
P31947;
43-51
88.89CL;V3W;CA;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-041 Heteromer
P31947;
43-51
88.89CL;V1Q;PEG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-159 Heteromer
P31947;
43-51
88.89CL;V2T;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-168 Heteromer
P31947;
43-51
88.89CL;V3T;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-085 Heteromer
P31947;
43-51
88.89CL;V4B;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-165 Heteromer
P31947;
43-51
88.89CL;V3K;GOL;CA;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-027 Heteromer
P31947;
43-51
88.89CL;L3V;CA;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-043 Heteromer
P31947;
44-51
87.5V0Q;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-118 Heteromer
P31947;
44-51
87.5CL;GOL;UHW;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-128 Heteromer
P31947;
43-50
87.5UGQ;CL;CA;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-129 Heteromer
P31947;
43-50
87.5P7T;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-167 Heteromer
P31947;
43-50
87.5CL;V3Q;MG;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-045 Heteromer
P31947;
44-51
87.5CL;V1H;MG;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-178 Heteromer
P31947;
43-50
87.5CL;V4K;CA;GOL;
Structure of importin a2 bound to p65-NLS Heteromer
P52293;
299-306
100
14-3-3 sigma with p65 (RelA) binding site pS45 and covalently bound PC2046 Heteromer
P31947;
43-49
85.71UQN;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-119 Heteromer
P31947;
43-49
85.71CL;CA;UHT;
Crystal Structure of Brd4 Bromodomain 1 in Complex with Acetylated Rel Peptide Heteromer
O60885;
308-314
100
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-160 Heteromer
P31947;
43-49
85.71CL;V2W;MG;GOL;
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-110 Heteromer
P31947;
43-48
100S9E;PEG;
Human SETD6 in complex with RelA Lys310 peptide Heteromer
Q8TBK2;
307-312
10010×EDO;SAM;
Structure of importin a2 bound to the p50- and p65-NLSs Heteromer
P19838; P52293;
299-304
100
Brd4 Bromodomain 2 in Complex with Acetylated Rel Peptide Heteromer
O60885;
308-312
100DTT;
14-3-3 sigma with RelA/p65 binding site pS281 Heteromer
P31947;
280-282
100
Human SETD6 in complex with RelA Lys310 Heteromer
Q8TBK2;
310-310
100SAM; 11×EDO;

4 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
9bdv.1.Amonomer0.8419-294
97.21
1ooa.1.Bmonomer0.7618-291
44.60
1nfi.1.Amonomer0.7620-313
99.67
2lww.1.Bmonomer0.52427-491
81.54

11 SWISS-MODEL models built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 29bdv.1.Amonomer0.846-281
95.47
Isoform 21ooa.1.Bmonomer0.776-278
44.76
Isoform 21nfi.1.Amonomer0.767-300
98.00
Isoform 22lww.1.Bmonomer0.52414-478
81.54
Isoform 39bdv.1.Amonomer0.8219-284
97.11
Isoform 31nfi.1.Amonomer0.7420-303
99.66
Isoform 31ooa.1.Bmonomer0.7318-281
45.85
Isoform 32lww.1.Bmonomer0.51417-481
81.54
Isoform 49bdv.1.Amonomer0.8019-291
97.53
Isoform 41nfi.1.Amonomer0.7520-310
98.99
Isoform 42lww.1.Bmonomer0.52424-488
81.54